This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Preclinical findings from Stanford University may help explain the lack of efficacy with CAR T-cell therapies in some patients with large B-cell lymphomas. The researchers pinpointed the CD58–CD2 axis as a novel resistance mechanism, then figured out how next-generation CAR T cells could be engineered to overcome this issue.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
January 2021
Volume 11, Issue 1
Volume 11, Issue 1
Uncovering a Culprit in CAR-T Resistance
Jump to section
Advertisement